Unlock instant, AI-driven research and patent intelligence for your innovation.

Non-specific immunostimulating agents

A use, virus envelope technology, applied in the direction of vaccines, antifungal agents, antiviral agents, etc.

Inactive Publication Date: 2013-11-20
PEVION BIOTECH
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Virions cannot replicate, but are pure fusogenic vesicles

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-specific immunostimulating agents
  • Non-specific immunostimulating agents
  • Non-specific immunostimulating agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] Example 1 (preparative example): Reagents used in the preparation and working examples

[0113] Reagent: octaethylene glycol-mono-(n-dodecyl) ether (OEG, C 12 E. 8 ) was purchased from Fluka Chemie GmbH - (Buchs, Switzerland). Sucrose (Eur. Phar.) was purchased from Merck (Dietikon, Switzerland). Egg phosphatidylcholine (PC) was obtained from Lipoid (Cham, Switzerland). 1-Oleoyl-3-palmitoyl-rac-glycero-2-phosphoethanolamine was obtained from Bachem (Bubendorf, Switzerland). Bio-Beads SM2 were purchased from Bio-Rad Laboratories (Glattbrugg, Switzerland). Cholesteryl N(trimethylammoniumethyl)carbamate chloride (TC-chol) was purchased from Merck Eprova (Schaffhausen, Switzerland).

[0114] Influenza virus A / Singapore / 6 / 86 (A / Sing) strain and other influenza A strains proliferate in the allantoic cavity of embryonated eggs (Gerhard, W. (1976), Journal of Experimental Medicine 144:985 -995), obtained from Berna Biotech AG (Bern, Switzerland), purified as described b...

Embodiment 2

[0115] Example 2 (preparation example): Preparation of standard virus particles as influenza virus particles

[0116] For a final volume of 4 ml, 32 mg of egg PC and 8 mg of OPPE were dissolved in 3 ml of PBS, 100 mM OEG (PBS / OEG). 2 mg of HA of inactivated influenza A / Singapore / 6 / 86 virus or another influenza A strain was centrifuged at 100,000 xg for 1 hour at 4°C and the pellet was dissolved in 1 ml of PBS / OEG. Detergent-dissolved phospholipids and virus were mixed and sonicated for 1 min. This mixture was centrifuged at 100,000 xg for 1 hour at 18°C. Virus particles were formed by removing the detergent using two 1.5 g moistened SM2 Bio-Beads shaking each for 1 hour at room temperature. Newly formed virus particles were then sterile filtered (0.22 μm).

Embodiment 3

[0117] Example 3 (Preparation Example): Preparation of Virus Particles Containing TC-Chol

[0118] Virus particles containing TC-Chol were prepared by a detergent removal method. For a final volume of 4 ml, 32 mg of egg PC and 8 mg of OPPE and 5 mg of cholestenyl N-(trimethylammoniumethyl)carbamate chloride (TC-Chol) were dissolved in 2.6 ml of PBS, 100 mM OEG (PBS / OEG). 2 mg of HA of inactivated influenza A / Singapore / 6 / 86 virus or another influenza A strain was centrifuged at 100,000 xg for 1 hour at 4°C and the pellet was dissolved in 1 ml of PBS / OEG. Detergent-dissolved phospholipids and virus were mixed with 0.4 ml of 50% (w / v) sucrose and sonicated for 1 min. The mixture was centrifuged at 100,000 xg for 1 hour at 18°C. Virus particles were formed by removing the detergent using two 1.5 g moistened SM2 Bio-Beads shaking each for 1 hour at room temperature. Newly formed virus particles were then sterile filtered (0.22 μm) and aliquoted in sterile glass vials. The c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to a lipid vesicle. The invention further relates to the use of such a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and / or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.

Description

technical field [0001] The present invention relates to the use of a lipid vesicle for the preparation of a medicament for non-specifically stimulating an animal's immune response to a disease or disorder. The invention further relates to a method of non-specifically stimulating an immune response in an animal, ie, treating, eliminating and / or preventing a disease or disorder, which method involves administering a lipid vesicle to an animal in need thereof. The lipid vesicle contains in its lipid membrane at least one viral envelope protein. Background technique [0002] It is desirable to increase the general resistance against diseases, especially against infectious diseases, by means of a non-specific stimulation of the immune system of the body. At the same time, the importance of the immune system for the suppression and elimination of neoplastic diseases has become apparent and recognized. However, due to the often complex composition and multiple interactions of dif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/145
CPCA61K39/145C12N2760/16134A61K39/0225A61K2039/5258A61K2039/53A61K2039/585C12N2760/12034C12N2760/16142A61K39/12A61P3/10A61P31/00A61P31/04A61P31/10A61P31/12A61P33/00A61P35/00A61P35/02A61P37/00A61P37/04
Inventor 克里斯蒂娜·莫泽安德烈亚斯·卡默里纳尔多·楚尔布里根
Owner PEVION BIOTECH